Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said preliminary, unaudited net product revenue for its lead narcolepsy drug WAKIX reached approximately $868 million in 2025, setting the …
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion Read More